ALPCO
Brenda McDermott is an experienced Immunoassay Development Scientist at ALPCO, with a focus on developing and implementing new products from concept to market within US and European regulatory frameworks since July 2013. Prior to this role, Brenda held positions as a Scientist at AstraZeneca, where contributions were made to oncology research through in-vitro biology, and at Praecis Pharmaceuticals and ImmuLogic Pharmaceutical Corporation as a Scientist and Senior Research Associate, respectively. Brenda holds a Bachelor of Arts degree in Biology from Susquehanna University, attained in 1986.